Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

McMaster University

$277,038.00

D-dimer to select patients with a first unprovoked venous thromboembolism who can have anticoagulants stopped at 3 months: Extension of follow-up.

FY 2012-13

Summary
Patients who have a venous thrombosis ("blood clot") in their legs or lungs without apparent cause (e.g. no recent surgery or cancer) have about a 50% risk of another thrombosis in 10 years if they stop anticoagulant therapy ("blood thinners"). A new episode of thrombosis is very unlikely if patients remain on treatment but anticoagulant therapy increases bleeding and is a burden. If we could identify the patients with a low risk of another thrombosis they could stop treatment, whereas those with a high risk could stay on treatment. There is evidence that normal D-dimer blood tests indicate a low risk of another thrombosis. We are doing a study to determine if it is correct to stop treatment after 3 months in patients with unprovoked thrombosis who have normal D-dimer results; those with normal results stop therapy and those with abnormal results continue therapy. We then follow patients to make sure they remain well. By March 2013 we will have followed the 410 patients in this study for an average of 2.5 years, which is the length of time for which we were funded. We are now asking for funds to follow these patients for an additional 3 years. This would more than double follow-up (to an average of 5.5 years), would be relatively inexpensive to do (less than half the original study cost), and would greatly increase the knowledge gained from this study. In particular, it would enable us to: 1) obtain a much better measurement of the rate of having another thrombosis, and to compare this rate between males and females; and 2) determine the long-term, as well as just the short-term, risk of another thrombosis. Both are very important. First, the results may have different meaning in males and females, because the risk of another thrombosis is much higher in males. Second, it would be wrong to stop treatment if normal D-dimer results did not mean a low long-term, as well as short-term, risk of another thrombosis.
Program
Operating Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
266781
Name
Kearon Clive
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinical Investigation - D: Cardiovascular Systems
Projecttitle
D-dimer to select patients with a first unprovoked venous thromboembolism who can have anticoagulants stopped at 3 months: Extension of follow-up.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$277,038
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Anticoagulant Therapy; Clinical Management; Clinical Outcomes; Cohort Study; D-Dimer; Venous Thromboembolism
Abstract
Patients who have a venous thrombosis ("blood clot") in their legs or lungs without apparent cause (e.g. no recent surgery or cancer) have about a 50% risk of another thrombosis in 10 years if they stop anticoagulant therapy ("blood thinners"). A new episode of thrombosis is very unlikely if patients remain on treatment but anticoagulant therapy increases bleeding and is a burden. If we could identify the patients with a low risk of another thrombosis they could stop treatment, whereas those with a high risk could stay on treatment. There is evidence that normal D-dimer blood tests indicate a low risk of another thrombosis. We are doing a study to determine if it is correct to stop treatment after 3 months in patients with unprovoked thrombosis who have normal D-dimer results; those with normal results stop therapy and those with abnormal results continue therapy. We then follow patients to make sure they remain well. By March 2013 we will have followed the 410 patients in this study for an average of 2.5 years, which is the length of time for which we were funded. We are now asking for funds to follow these patients for an additional 3 years. This would more than double follow-up (to an average of 5.5 years), would be relatively inexpensive to do (less than half the original study cost), and would greatly increase the knowledge gained from this study. In particular, it would enable us to: 1) obtain a much better measurement of the rate of having another thrombosis, and to compare this rate between males and females; and 2) determine the long-term, as well as just the short-term, risk of another thrombosis. Both are very important. First, the results may have different meaning in males and females, because the risk of another thrombosis is much higher in males. Second, it would be wrong to stop treatment if normal D-dimer results did not mean a low long-term, as well as short-term, risk of another thrombosis.
Competitiondate
201209
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kearon, Clive
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $277,038~ $0~
McMaster University - $277,038 Grant (2012-13) | Canada Spends